Phytomedical partners with LATITUDE Pharmaceuticals on lead anti cancer compound for glioblastoma

PhytoMedical Technologies, Inc. has announced their partnership with LATITUDE Pharmaceuticals, Inc. to develop an IV Formulation for its lead anti cancer compound for glioblastoma. LATITUDE Pharmaceuticals, Inc. is a widely recognized expert in the area of drug formulations and delivery systems.

“Given LATITUDE’s successful track record in formulation development, we are extremely pleased to have partnered with such an innovative group of experts,” commented PhytoMedical, President, CEO, Greg Wujek. “The development and subsequent testing of the IV Formulation are key components in PhytoMedical’s quest to provide physicians and their patients with an effective treatment option for this most difficult to treat and often deadly form of brain cancer.”

“We are very happy to be chosen by PhytoMedical for this assignment because of our previous successes,” noted LATITUDE’s president, Dr. Andrew Chen. “Having the right formulation is instrumental to cost-effective, efficient, and expedient drug development. We look forward to contributing to the success of PhytoMedical’s exciting compound.”

Nearly two years ago PhytoMedical began the testing of several different anti cancer compounds which are based on the science of bis-intercalation, the process by which the anti-cancer compounds bind to the DNA of a cancer cell, disallowing replication and resulting in cell death. In a February press release outlining the results of a crucial in vivo efficacy and toxicity evaluation, it was announced that the Company’s patented anti-cancer compound proved to be the least toxic yet extremely effective in controlling the growth of SF295 human glioblastoma xenografts.

In all cases where specimens were treated for human glioblastoma brain cancer using PhytoMedical’s patented compound, researchers reported: a significant reduction in tumor size; prolonged lifespan of 46%-plus for the treated group versus the control group; notable enhanced chemotherapeutic effect of the compound; and even an observation of “tumor cured” in one of the specimens that had been carrying the deadly glioblastoma cancer.

www.latitudepharma.com and www.PhytoMedical.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers uncover key genes linked to DCIS progression